CARD15: a Pleiotropic Autoimmune Gene That Confers Susceptibility to Psoriatic Arthritis  by Rahman, P. et al.
Am. J. Hum. Genet. 73:677–681, 2003
677
Report
CARD15: a Pleiotropic Autoimmune Gene That Confers Susceptibility
to Psoriatic Arthritis
P. Rahman,1 S. Bartlett,1 F. Siannis,2 F. J. Pellett,3 V. T. Farewell,2 L. Peddle,1 C. T. Schentag,3
C. A. Alderdice,1 S. Hamilton,1 M. Khraishi,1 Y. Tobin,1 D. Hefferton,1 and D. D. Gladman3
1St. Clare’s Mercy Hospital, Memorial University of Newfoundland, St. John’s, Newfoundland; 2Medical Research Council Biostatistics Unit,
Institute of Public Health, Cambridge, United Kingdom; and 3Center for Prognosis Studies in Rheumatic Diseases, University Health Network,
University of Toronto, Toronto
A recent genomewide scan in psoriatic arthritis (PsA) revealed a susceptibility locus at 16q. This region overlaps
CARD15, a susceptibility gene in Crohn disease. The possibility of a common susceptibility gene between PsA and
Crohn disease is further supported by epidemiological studies that note an increased incidence of psoriasis in subjects
with Crohn. We screened 187 patients with PsA and 136 healthy controls, all from Newfoundland, for the three
common, independent sequence variants of CARD15 (R702W, leu1007fsinsC, and G908R), which were detected
by polymerase chain reaction by use of allele-speciﬁc primers and visualized through gel electrophoresis. In total,
53/187 (28.3%) probands with PsA had at least one variant of the CARD15 gene, compared with 16/136 (11.8%)
controls (odds ratio 2.97; 95% conﬁdence interval 1.61–5.47; ). Allele frequencies of R702W,Pp .0005
leu1007fsinsC, and G908R were 10.43%, 3.21%, and 1.61%, respectively, in patients with PsA, compared with
3.31%, 2.57%, and 0.37%, respectively, in the control patients. CARD15 conferred susceptibility to PsA inde-
pendent of HLA-Cw*0602. Thus, CARD15 represents a pleiotropic autoimmune gene and is the ﬁrst non-MHC
gene to be associated with PsA.
Psoriasis (MIM 177900) is a chronic inﬂammatory hyper-
proliferative skin disorder that affects 1%–3% of the
population (Goodﬁeld 1994). Psoriatic arthritis (PsA) has
been deﬁned as an inﬂammatory arthritis associatedwith
psoriasis that occurs in up to one-third of the patients
with psoriasis (Wright and Moll 1976; Gladman et al.
1987). The etiology of PsA remains unknown but likely
results from an interplay between genetic, immunolog-
ical, and environmental factors (Gladman 2002). Mul-
tiple lines of evidence support a genetic basis of PsA. A
large epidemiological study in the United Kingdom re-
ported strong familial clustering of PsA with a relative
risk of 55% for affected ﬁrst-degree relatives (Moll and
Wight 1973). Association studies implicate the HLA loci
of the major histocompatibility complex (MHC) in pso-
riasis and PsA (Gladman 2002). The strongest associa-
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tion is between psoriasis and HLA-Cw*0602, with lesser
associations with HLA-B13, HLA-B17, and HLA-B57.
In PsA, the association with HLA-Cw*0602 is less pro-
found and is most evident in patients with PsA with an
early onset of psoriasis (Enerback et al. 1997; Gladman
et al. 1999).
Recent completion of the ﬁrst-ever genomewide linkage
scan in PsA, by use of 1,000 microsatellite markers in
178 patients with PsA from 39 Icelandic families, revealed
a LOD score of 2.17 on chromosome 16q (Karason et
al. 2003). Further analysis, conditional on paternal
transmission to affected individuals, resulted in a LOD
score of 4.19. The peak of this LOD score is within 20
Mb of the CARD15 gene (MIM 605956; GenBank ac-
cession number 64127). It is interesting that a region
overlapping CARD15 has also been implicated by a ge-
nomewide scan in psoriasis, in which a LOD score of
2.5 was reported (Nair et al. 1997). The CARD15 gene
has convincingly been shown to confer susceptibility to
Crohn disease (MIM 266600) (Hugot et al. 2001; Ogura
et al. 2001). The possibility of a common susceptibility
gene between psoriasis/PsA and Crohn disease is further
supported by epidemiological studies that note an in-
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Table 1
Genotypes of CARD15 Variants in Patients with PsA and Healthy Controls
GENOTYPE
ALLELE FREQUENCY OF
R702W in leu1007FsinsC in G908R in
Subjects with PsA Controls Subjects with PsA Controls Subjects with PsA Controls
Mutated/mutated 4 0 0 0 0 0
Mutated/wild type 31 9 12 7 6 1
Wild type/wild type 152 127 175 129 180 134
Total 187 136 187 136 186 135
creased incidence of psoriasis and PsA in subjects with
Crohn disease (Lee et al. 1990; Nair et al. 1997).
In this study, we set out to determine the prevalence
of the three common independent sequence variants
of CARD15 mutations, arg702 to trp (R702W), leu
1007fsinsC, and gly908 to arg (G908R) in PsA.
The study was approved by the local ethics committee,
and informed consent was obtained from all patients. All
subjects were identiﬁed from the province of Newfound-
land and were examined by a single rheumatologist (P.R.).
PsA was diagnosed as an inﬂammatory arthritis in pa-
tients with psoriasis, in the absence of other etiologies
for inﬂammatory arthritis. Information collected in-
cluded variables related to disease pattern, joint damage,
extent of psoriasis, extra-articular features, medication
history, and surgeries. The control subjects were not re-
lated and were all examined to ensure that they had no
autoimmune disease.
Genomic DNA was isolated from peripheral whole
blood collected in EDTA by use of a salting-out tech-
nique (PromegaWizard Genomic DNA PuriﬁcationKit).
For the CARD15 genotyping, 50 ng of DNA was used
for each PCR reaction. All subjects were genotyped for
the R702W (SNP8; exon 4), G908R (SNP12; exon 8),
and Leu1007fsinsC (SNP13; exon 11) variants. Reaction
products were visualized using agarose gel electrophore-
sis. All samples were scored as wild type/wild type, wild
type/mutated, or mutated/mutated. The laboratory sci-
entist was blind to the clinical diagnosis.
The R702W (Hugot SNP8 [GenBank accessionnumber
G67950]) variant of the CARD15 gene was genotyped
by use of the PCR-ARMS technique (Vermeire et al.
2002). Appropriate internal, water, and known controls
were used for each R702W reaction (Lesage et al. 2002).
The primers were wild-type forward (5′-ATCTGAGAA-
GGCCCTGCTCC-3′), mutated forward (5′-ATCTGAG-
AAGGCCCTGCTCT-3′), reverse (5′-CCCACACTTAG-
CCTTGATG-3′), constant forward (5′-GCAGACATTG-
ATTTTACACAG-3′), and constant reverse (5′-TGAGG-
CAAAACAACTGAGAC-3′). These primers were syn-
thesized by Integrated DNATechnologies. The PCR con-
ditions are available from the authors on request.
The missense mutation G908R (Hugot SNP12 [Gen-
Bank accession number G67951]) creates a restriction
endonuclease site for HhaI. The double-stranded DNA
fragment was ampliﬁed using primers 5′-CCCAGCTCC-
TCCCTCTTC-3′ and 5′-AAGTCTGTAATGTAAAGC-
CAC-3′. The presence of a variant allele produces two
bands of 138 bp and 242 bp, and a wild-type allele
results in one band of 380 bp following DNA ampliﬁ-
cation and digestion with HhaI.
The Leu1007fsinsC (Hugot SNP13 [GenBank acces-
sion number G67955]) was genotyped using multiplex
PCR. The primers were 5′-CTG AGC CTT TGT TGA
TGA GC-3′ (forward), 5′-TCT TCA ACC ACA TCC
CCA TT-3′ (reverse), 5′-CAG AAG CCC TCC TGC
AGG CCC T-3′ (wild type), and 5′-CGC GTG TCA TTC
CTT TCA TGG GGC-3′ (mutated). The wild-type allele
produced a band of 319 bp, and the mutation produced
a band of 214 bp.
For HLA genotyping, 200 ng of genomic DNA was
ampliﬁed using the Dynal RELI SSO HLA-Cw* typing
kit. PCR amplicons were identiﬁed by a reverse line assay
by use of sequence-speciﬁc oligonucleotide probes.Assay
results were interpreted by use of the Pattern Matching
Program provided by Dynal.
Logistic regression was used to calculate odds ratio
(OR) estimates and corresponding 95% CIs that relate
CARD15 mutations and PsA, as well as to examine the
joint risk associated with CARD15 mutations andHLA-
Cw*0602. Fisher’s exact test was used to test for the
presence of linkage disequilibrium between all possible
combinations of the CARD15 variants. Cox’s semipara-
metric method (Cox 1972) was used to examine the
association between age at onset of psoriasis and age at
onset of PsA and the CARD15 and HLA-CW*0602
genotypes. For the genotype/phenotype correlations,
Fisher’s exact test was used to examine associations be-
tweenCARD15 mutations and selected binary variables.
Since the genotype/phenotype correlations were an ex-
ploratory analysis for future studies with larger samples
of patients with PsA and the appropriate error structure
for multiplicity adjustments in the rheumatological con-
text is not well deﬁned (Cook and Farewell 1996), for-
mal adjustments were not made for multiple testing.
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Table 2
Logistic Regression for Univariate CARD15
Variants
Sequence Variant OR 95% CI P
R702W 3.50 1.51–7.01 .0027
1007 1.26 .48–3.30 .63
G908R 4.47 .53–7.52 .17
CARD15 2.97 1.61–5.47 .0005
Table 3
Logistic Regression for Multivariate CARD15 Variants
Sequence Variant OR 95% CI P
R702W 3.91 (3.70) 1.45–10.54 (1.82–7.54) .0071 (.0003)
1007 1.50 (3.79) .50–4.47 (1.87–7.68) .47 (.0002)
G908R 3.68 (3.68) .43–31.56 (1.82–7.46) .23 (.0003)
CARD15 3.57 (4.00) 1.69–7.54 (1.96–8.17) .0009 (.0001)
NOTE.—All values are in comparison with HLAc6.
Thus, no deﬁnitive conclusions can be drawn regarding
the genotype/phenotype correlations.
In total, 187 unrelated white patients with PsA (100
males and 87 females) were assessed. For one patient,
G908R information was missing. The mean age and dis-
ease duration of patients with PsA were 47.93 years (SD
10.83) and 10.94 years (SD 8.50), respectively, and the
mean age for the 136 white controls (56 males and 80
females) was 44.87 years (SD 14.01). All subjects were
“native Newfoundlanders” who were whites of North-
ern European ancestry. Allele frequencies of R702W,
leu1007fsinsC, and G908R were 10.43%, 3.21%, and
1.61%, respectively, in patients with PsA, compared
with 3.31%, 2.57%, and 0.37%, respectively, in the 136
control patients (table 1). There was no evidence against
the assumption of Hardy-Weinberg equilibrium in the
controls for all CARD15 variants.
Tables 2 and 3 provide results of univariate logistic
regressions of case/control status for models, including
variables deﬁned by anyCARD15mutation and the sepa-
rate CARD15 mutations. Only four patients were homo-
zygous for anyCARD15mutation (all R702W), andnone
of the controls were homozygous for any CARD15 mu-
tation (table 1). A formal dominance test provided no
evidence of differential risk for heterozygotes and homo-
zygotes. Therefore, all analyses combine individuals ho-
mozygous and heterozygous for allele R702W. The OR
for the R702W variant was 3.50 (95% CI 1.51–7.01),
; for the leu1007fsinsC variant, the OR wasPp .0027
1.26 (95% CI 0.48–3.30), ; and for the G908RPp .63
variant, the OR was 4.47 (95% CI 0.53–7.52), Pp
(table 2). There was no evidence of any linkage dis-.17
equilibrium among the three analyzed polymorphisms.
Only a single control individual had two CARD15 mu-
tations (leu1007fsinsC and R702W). There was no evi-
dence, however, that this was inconsistent with inde-
pendence assumptions in cases or controls for any pair
of mutations (minimum P value .13). In total, 53/187
(28.3%) patients with PsA had at least one variant of
the CARD15 gene, compared with 16/136 (11.8%) con-
trols (OR 2.97; 95% CI 1.61–5.47; ). ThePp .0005
prevalence of the CARD15 mutation was similar in fa-
milial PsA (14/54; 25.9%), deﬁned as at least one other
affected ﬁrst-degree relative, as compared with sporadic
PsA (39/133; 29.3%).
In total, 176 subjects with PsA were genotyped for
HLA-Cw*0602. Of the 176 subjects with PsA, 60
(34.1%) had at least one HLA-Cw*0602 allele, as com-
pared with 11/90 (12.2%) of the controls for whom
HLA information was available (OR 3.72; 95% CI
1.84–7.51; ). Table 4 shows the relationship be-P ! .001
tween the presence of HLA-Cw*0602 and the three
CARD15 mutations in patients with PsA. As can be seen
from the table, there was no correlation noted between
these variables. The ORs associated with the CARD15
variants in the multivariate models that include the
HLA-Cw*0602 variable differ little from those in the
univariate models. In addition, there was no evidence of
interaction effects on disease incidence between the
CARD15 variables and the HLA-Cw*0602 indicator. In
particular, the 15 individuals with both an HLA-
Cw*0602 allele and CARD15 gene were all patients
with PsA, but there was no evidence that this was in-
consistent with a multiplicative effect of the two factors
( ).Pp .15
One of themost consistent associations reported todate
on psoriasis and PsA is the early age at onset of psoriasis
in subjects carrying HLA-Cw*0602 (Enerback et al.
1997; Gladman et al. 1999). On the basis of a Cox
regression model for onset times and explanatory vari-
ables coding for HLA-Cw*0602 and the CARD15 genes,
we noted a strong relationship between an earlier age
at the onset of psoriasis and the presence of HLA-
Cw*0602 ( ). There is some evidence thatP ! .001
G908R is associated with a later age at onset of psoriasis
( ), with slightly less evidence in the presence ofPp .045
HLA-Cw*0602 ( ). No other relationship wasPp .061
noted between theCARD15 mutations and onset of pso-
riasis or PsA.
With respect to genotype/phenotype correlations, those
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Table 4
Relationship between HLA-Cw*0602 and CARD15 Variants
HLACw*0602
STATUS
NO. OF AFFECTED SUBJECTS WITH VARIANT
R702Wa 1007b G908Rc
Absent Present Absent Present Absent Present
Absent 95 21 106 10 111 5




carrying the R702W mutation had greater tendency
for corticosteroid use (9/35 vs. 17/152 [ ]) andPp .03
joint surgeries related to PsA (5/34 vs. 7/151 [Pp
]). No associations were noted between CARD15.05
mutations and disease pattern, damaged joints, extent
of psoriasis, extra-articular features, and/or use of dis-
ease-modifying agents. Of note, Crohn disease was iden-
tiﬁed in 2/187 (1.1%) probands with PsA, of whom 1
carried a CARD15 mutation (R702W heterozygote).
To our knowledge, this is the ﬁrst study to examine the
prevalence ofCARD15mutations in PsA. It is interesting
that a recent Italian study failed to demonstrate a strong
association between the same three CARD15 variants
and uncomplicated psoriasis (Borgiani et al. 2002). Lack
of association between NOD2 3020InsC frameshift mu-
tation and psoriasis has also been reported by Nair et
al. (2001). It is conceivable that the CARD15 mutation
is more speciﬁc to PsA than uncomplicated psoriasis.
Alternatively, an enhanced signal-to-noise ratio, like that
in Newfoundland, may be necessary to establish this
association. Newfoundland is a well-recognized genetic
isolate, the homogeneity of which resembles that of re-
ligious isolates such as the Hutterites and the Amish
(Bear et al. 1988). Thus, the genetic homogeneity of the
Newfoundland population, coupled with the relative en-
vironmental/cultural homogeneity, may offer the op-
portunity to detect modest signals. Given the uniqueness
of said population, conﬁrmation of our ﬁnding in an-
other population or ethnic group is prudent prior to
generalizing that CARD15 confers susceptibility to PsA.
The CARD15 gene may shed further light on the
pathogenesis of PsA, as theCARD15mutations have been
implicated in altering recognition of the bacterial lipo-
polysaccharide (LPS) (Ogura et al. 2001). This hypothesis
has been supported by functional experiments, as 1007fs
mutations decreased the NF-kB activation by the LPS
(Hugot and Cho 2002). This is intriguing, in that a tem-
poral relationship has long been noted between bacterial
infections (such as Streptococcus) and the development
and exacerbation of psoriasis and PsA (Vasey 1985).
In summary, CARD15 is the ﬁrst candidate gene iden-
tiﬁed in PsA that resides outside the MHC. The risk for
CARD15 to be associated in our population with PsA
(OR 2.97) is comparable with that seen for HLA-
Cw*0602 (OR 3.72), the allele most consistently rec-
ognized to be associatedwith psoriasis and PsA.CARD15
confers its disease risk independent of HLA-Cw*0602,
as no relationship between CARD15 mutations and
HLA-Cw*0602 was noted. Finally, our study suggests
that CARD15 is a pleiotropic autoimmune gene, since
it confers susceptibility to Crohn disease (Hugot et al.
2001; Ogura et al. 2001), Blau syndrome (Miceli-Rich-
ard et al. 2001), and, now, PsA. One of the central ge-
netic factors in autoimmune diseases is the MHC; how-
ever, it is unlikely that this locus solely accounts for the
similar genetic predisposition. CARD15 may represent
a non-MHC genetic locus that results in susceptibility
to multiple autoimmune diseases.
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